These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27005869)

  • 41. The ATHENA HPV study underrepresents "other" high-risk HPV genotypes when compared with a diverse New York City population.
    Ramos Rivera G; Khader SN; Lajara S; Schlesinger K; Goldstein DY; Naeem RC; Suhrland MJ; Fox AS
    Cytopathology; 2017 Oct; 28(5):413-418. PubMed ID: 28730704
    [TBL] [Abstract][Full Text] [Related]  

  • 42. γH2Ax Expression as a Potential Biomarker Differentiating between Low and High Grade Cervical Squamous Intraepithelial Lesions (SIL) and High Risk HPV Related SIL.
    Leventakos K; Tsiodras S; Kelesidis T; Kefala M; Kottaridi C; Spathis A; Gouloumi AR; Pouliakis A; Pappas A; Sioulas V; Chrelias C; Karakitsos P; Panayiotides I
    PLoS One; 2017; 12(1):e0170626. PubMed ID: 28118377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of HPV RNA molecules in stratified mucin-producing intraepithelial lesion (SMILE) with concurrent cervical intraepithelial lesion: a case report.
    Fukui S; Nagasaka K; Iimura N; Kanda R; Ichinose T; Sugihara T; Hiraike H; Nakagawa S; Sasajima Y; Ayabe T
    Virol J; 2019 Jun; 16(1):76. PubMed ID: 31159808
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection.
    Zheng J
    Int J Clin Exp Pathol; 2015; 8(1):875-80. PubMed ID: 25755789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The health outcome and the costs of primary HPV testing with dual-stain cytology triage in cervical cancer screening.
    Tjalma WAA
    Pol J Pathol; 2018; 69(3):319-320. PubMed ID: 30509060
    [No Abstract]   [Full Text] [Related]  

  • 46. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
    Ge Y; Christensen P; Luna E; Armylagos D; Schwartz MR; Mody DR
    Cancer Cytopathol; 2017 Aug; 125(8):652-657. PubMed ID: 28574670
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High risk HPV testing in the triage of repeat ASC-US and LSIL.
    Veijalainen O; Tuomisaari S; Luukkaala T; Mäenpää J
    Acta Obstet Gynecol Scand; 2015 Sep; 94(9):931-6. PubMed ID: 26053676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Analysis of three strategies to increase screening coverage for cervical cancer in the general population of women aged 60 to 70 years: the CRICERVA study.
    Acera A; Manresa JM; Rodriguez D; Rodriguez A; Bonet JM; Sanchez N; Hidalgo P; Soteras P; Toran P; Trapero-Bertran M; Lozano I; De Sanjose S
    BMC Womens Health; 2014 Jul; 14():86. PubMed ID: 25026889
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Silent High Grade Cervical Intraepithelial Neoplasia in Atypical Smears from Liquid Based Cervical Cytology - Three Years Experience in Thammasat University Hospital.
    Lertvutivivat S; Chanthasenanont A; Chanthasenanont A; Muangto T; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
    Asian Pac J Cancer Prev; 2016; 17(9):4353-4356. PubMed ID: 27797243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I.
    Wu R; Belinson SE; Du H; Na W; Qu X; Wu R; Liu Y; Wang C; Zhou Y; Zhang L; Belinson JL
    Int J Gynecol Cancer; 2010 Nov; 20(8):1411-4. PubMed ID: 21051986
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human papillomavirus genotype profiles and cytological grades interlinkages in coinfection with HIV.
    Karani LW; Musyoki S; Orina R; Nyamache AK; Khayeka-Wandabwa C; Nyagaka B
    Pan Afr Med J; 2020; 35():67. PubMed ID: 32537071
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of self-collected vaginal specimens for the detection of high-risk human papillomavirus infection and the prediction of high-grade cervical intraepithelial lesions in a high-burden, low-resource setting.
    Toliman PJ; Kaldor JM; Badman SG; Phillips S; Tan G; Brotherton JML; Saville M; Vallely AJ; Tabrizi SN
    Clin Microbiol Infect; 2019 Apr; 25(4):496-503. PubMed ID: 29906593
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomised healthcare policy evaluation of organised primary human papillomavirus screening of women aged 56-60.
    Lamin H; Eklund C; Elfström KM; Carlsten-Thor A; Hortlund M; Elfgren K; Törnberg S; Dillner J
    BMJ Open; 2017 May; 7(5):e014788. PubMed ID: 28566363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Value of Human Papillomavirus E6/E7 mRNA Detection in Screening for Cervical Cancer in Women Positive for Human Papillomavirus DNA or.
    Han L; Husaiyin S; Zhao F; Rezhake R; Niyazi M
    Clin Lab; 2018 Sep; 64(9):1363-1371. PubMed ID: 30274003
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.